Slide 4 summarizes three things: Q3 results, year-to-date performance, and another update to our full-year 2025 guidance. We posted another solid quarter, delivering strong revenue and earnings growth and good margin expansion. Core growth came in at 9%, aided by the expected Spark deferral benefit. Excluding this, core growth in the quarter was around 5%, with all major businesses once again in positive territory.
Adjusted EBITDA margin was 14.5%, up more than 500 basis points from Q3 of 2024, supported by good growth and productivity. Moving to year-to-date performance, core growth came in around 3% after normalizing for last year's changes in Spark deferral and dealer inventory levels. Year-to-date adjusted EBITDA margin is around 13%, showing progress in Q3 over H1. Rounding out the column, through three quarters, we've delivered $0.82 of adjusted EPS, a 67% increase over the same period last year.
Moving to the column on the right, given our good year-to-date performance and strong momentum, we are again raising our full-year 2025 guidance. We now expect core revenue growth of approximately 4%, up from 3%-4% previously, and adjusted EPS of $1.10-$1.15 versus $1.05-$1.15 previously. Let's now turn to progress we made in the quarter in support of our three core priorities of growth, operations, and people. Beginning with growth on the left side of the chart, ours was well-balanced between volume and price and broad-based across the portfolio as ortho consumables, diagnostics, and implants all delivered growth.